Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

NVN1000, a novel nitric oxide-releasing compound, inhibits HPV-18 virus production by interfering with E6 and E7 oncoprotein functions.

Banerjee NS, Moore DW, Wang HK, Broker TR, Chow LT.

Antiviral Res. 2019 Jul 15;170:104559. doi: 10.1016/j.antiviral.2019.104559. [Epub ahead of print] No abstract available.

2.

Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification.

Banerjee NS, Moore DW, Broker TR, Chow LT.

Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):E11138-E11147. doi: 10.1073/pnas.1801156115. Epub 2018 Nov 1.

3.

Synthesis and Antiviral Evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a Potent Inhibitor of Transient HPV DNA Amplification.

Beadle JR, Valiaeva N, Yang G, Yu JH, Broker TR, Aldern KA, Harden EA, Keith KA, Prichard MN, Hartman T, Buckheit RW Jr, Chow LT, Hostetler KY.

J Med Chem. 2016 Dec 8;59(23):10470-10478. Epub 2016 Nov 28.

PMID:
27933957
4.

Genomic diversity and phylogenetic relationships of human papillomavirus 16 (HPV16) in Nepal.

Makowsky R, Lhaki P, Wiener HW, Bhatta MP, Cullen M, Johnson DC, Perry RT, Lama M, Boland JF, Yeager M, Ghimire S, Broker TR, Shrestha S.

Infect Genet Evol. 2016 Dec;46:7-11. doi: 10.1016/j.meegid.2016.10.004. Epub 2016 Oct 7.

5.

Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes.

Wang HK, Wei Q, Moldoveanu Z, Huh WK, Vu HL, Broker TR, Mestecky J, Chow LT.

Vaccine. 2016 Jun 8;34(27):3171-3177. doi: 10.1016/j.vaccine.2016.04.038. Epub 2016 Apr 23.

6.

Robust HPV-18 production in organotypic cultures of primary human keratinocytes.

Wang HK, Broker TR, Chow LT.

Methods Mol Biol. 2015;1249:93-109. doi: 10.1007/978-1-4939-2013-6_7.

PMID:
25348300
7.

Assessment of high-risk human papillomavirus infections using clinician- and self-collected cervical sampling methods in rural women from far western Nepal.

Johnson DC, Bhatta MP, Smith JS, Kempf MC, Broker TR, Vermund SH, Chamot E, Aryal S, Lhaki P, Shrestha S.

PLoS One. 2014 Jun 30;9(6):e101255. doi: 10.1371/journal.pone.0101255. eCollection 2014.

8.

Prevalence and correlates of cervico-vaginal clinical syndromes among women attending a health camp in Lalitpur district of Nepal.

Johnson D, Chamot E, Lhaki P, Broker TR, Steben M, Steben M, Shrestha S.

Kathmandu Univ Med J (KUMJ). 2013 Oct-Dec;11(44):268-73.

PMID:
24899318
9.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; authors of ICO Monograph Comprehensive Control of HPV Infections and Related Diseases Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Dec 31;31 Suppl 7:H1-31. doi: 10.1016/j.vaccine.2013.10.003.

PMID:
24332295
10.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Dec 30;31 Suppl 6:G1-31. doi: 10.1016/j.vaccine.2013.10.002. Review.

PMID:
24331817
11.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Dec 29;31 Suppl 5:F1-31. doi: 10.1016/j.vaccine.2013.10.001. Review.

PMID:
24331745
12.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; Authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Nov 22;31 Suppl 8:I1-31. doi: 10.1016/j.vaccine.2013.07.026. Review.

13.

Human papillomavirus infections: warts or cancer?

Chow LT, Broker TR.

Cold Spring Harb Perspect Biol. 2013 Jul 1;5(7). pii: a012997. doi: 10.1101/cshperspect.a012997. Review.

14.

HPV-18 E6 mutants reveal p53 modulation of viral DNA amplification in organotypic cultures.

Kho EY, Wang HK, Banerjee NS, Broker TR, Chow LT.

Proc Natl Acad Sci U S A. 2013 May 7;110(19):7542-9. doi: 10.1073/pnas.1304855110. Epub 2013 Apr 9.

15.

Global prevention and management of human papillomavirus related diseases: the pressing challenges and the compelling opportunities. Foreword.

Broker TR.

Vaccine. 2012 Nov 20;30 Suppl 5:vii-x. doi: 10.1016/j.vaccine.2012.07.071. No abstract available.

PMID:
23199970
16.

Therapy of human papillomavirus-related disease.

Stern PL, van der Burg SH, Hampson IN, Broker TR, Fiander A, Lacey CJ, Kitchener HC, Einstein MH.

Vaccine. 2012 Nov 20;30 Suppl 5:F71-82. doi: 10.1016/j.vaccine.2012.05.091. Review.

17.

The biology and life-cycle of human papillomaviruses.

Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA.

Vaccine. 2012 Nov 20;30 Suppl 5:F55-70. doi: 10.1016/j.vaccine.2012.06.083. Review.

PMID:
23199966
18.

Human papillomavirus and cancer prevention: gaps in knowledge and prospects for research, policy, and advocacy.

Franco EL, de Sanjosé S, Broker TR, Stanley MA, Chevarie-Davis M, Isidean SD, Schiffman M.

Vaccine. 2012 Nov 20;30 Suppl 5:F175-82. doi: 10.1016/j.vaccine.2012.06.092. Review.

19.

PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro.

Henken FE, Banerjee NS, Snijders PJ, Meijer CJ, De-Castro Arce J, Rösl F, Broker TR, Chow LT, Steenbergen RD.

Mol Cancer. 2011 Jun 10;10:71. doi: 10.1186/1476-4598-10-71.

20.

Nonconserved lysine residues attenuate the biological function of the low-risk human papillomavirus E7 protein.

Genovese NJ, Broker TR, Chow LT.

J Virol. 2011 Jun;85(11):5546-54. doi: 10.1128/JVI.02166-10. Epub 2011 Mar 16.

21.

Human papillomavirus (HPV) E7 induces prolonged G2 following S phase reentry in differentiated human keratinocytes.

Banerjee NS, Wang HK, Broker TR, Chow LT.

J Biol Chem. 2011 Apr 29;286(17):15473-82. doi: 10.1074/jbc.M110.197574. Epub 2011 Feb 14.

22.

The natural history of human papillomavirus infections of the mucosal epithelia.

Chow LT, Broker TR, Steinberg BM.

APMIS. 2010 Jun;118(6-7):422-49. doi: 10.1111/j.1600-0463.2010.02625.x. Review.

PMID:
20553526
23.

Anal-rectal cytology: correlation with human papillomavirus status and biopsy diagnoses in a population of HIV-positive patients.

Bean SM, Chhieng DC, Roberson J, Raper JL, Broker TR, Hoesley CJ, Eltoum IA, Jin G.

J Low Genit Tract Dis. 2010 Apr;14(2):90-6. doi: 10.1097/LGT.0b013e3181ba9bcd.

PMID:
20354415
24.

A highly efficient system to produce infectious human papillomavirus: Elucidation of natural virus-host interactions.

Chow LT, Duffy AA, Wang HK, Broker TR.

Cell Cycle. 2009 May 1;8(9):1319-23. Epub 2009 May 19.

PMID:
19342877
25.

Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6.

Wang X, Wang HK, McCoy JP, Banerjee NS, Rader JS, Broker TR, Meyers C, Chow LT, Zheng ZM.

RNA. 2009 Apr;15(4):637-47. doi: 10.1261/rna.1442309. Epub 2009 Mar 3.

26.

Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes.

Wang HK, Duffy AA, Broker TR, Chow LT.

Genes Dev. 2009 Jan 15;23(2):181-94. doi: 10.1101/gad.1735109. Epub 2009 Jan 8.

27.

Casein kinase II motif-dependent phosphorylation of human papillomavirus E7 protein promotes p130 degradation and S-phase induction in differentiated human keratinocytes.

Genovese NJ, Banerjee NS, Broker TR, Chow LT.

J Virol. 2008 May;82(10):4862-73. doi: 10.1128/JVI.01202-07. Epub 2008 Mar 5.

28.

Remodeling of the human papillomavirus type 11 replication origin into discrete nucleoprotein particles and looped structures by the E2 protein.

Sim J, Ozgur S, Lin BY, Yu JH, Broker TR, Chow LT, Griffith J.

J Mol Biol. 2008 Jan 25;375(4):1165-77. Epub 2007 Nov 12.

29.

Significance and possible causes of false-negative results of reflex human Papillomavirus infection testing.

Eltoum IA, Chhieng DC, Crowe DR, Roberson J, Jin G, Broker TR.

Cancer. 2007 Jun 25;111(3):154-9.

30.
31.

Effect of adenoviral mediated overexpression of fibromodulin on human dermal fibroblasts and scar formation in full-thickness incisional wounds.

Stoff A, Rivera AA, Mathis JM, Moore ST, Banerjee NS, Everts M, Espinosa-de-los-Monteros A, Novak Z, Vasconez LO, Broker TR, Richter DF, Feldman D, Siegal GP, Stoff-Khalili MA, Curiel DT.

J Mol Med (Berl). 2007 May;85(5):481-96. Epub 2007 Jan 12.

PMID:
17219096
32.

Strategies to enhance transductional efficiency of adenoviral-based gene transfer to primary human fibroblasts and keratinocytes as a platform in dermal wounds.

Stoff A, Rivera AA, Banerjee NS, Mathis JM, Espinosa-de-los-Monteros A, Le LP, De la Torre JI, Vasconez LO, Broker TR, Richter DF, Stoff-Khalili MA, Curiel DT.

Wound Repair Regen. 2006 Sep-Oct;14(5):608-17.

33.
34.
35.

Analysis of HPV DNA replication using transient transfection and cell-free assays.

Lin BY, Broker TR, Chow LT.

Methods Mol Med. 2005;119:331-48.

PMID:
16353340
36.
37.

Immune responses to human papillomavirus in genital tract of women with cervical cancer.

Nguyen HH, Broker TR, Chow LT, Alvarez RD, Vu HL, Andrasi J, Brewer LR, Jin G, Mestecky J.

Gynecol Oncol. 2005 Feb;96(2):452-61.

PMID:
15661235
38.

Cyclin/CDK regulates the nucleocytoplasmic localization of the human papillomavirus E1 DNA helicase.

Deng W, Lin BY, Jin G, Wheeler CG, Ma T, Harper JW, Broker TR, Chow LT.

J Virol. 2004 Dec;78(24):13954-65.

39.
40.

Simultaneous in situ detection of RNA, DNA, and protein using tyramide-coupled immunofluorescence.

Van Tine BA, Broker TR, Chow LT.

Methods Mol Biol. 2005;292:215-30.

PMID:
15507711
41.

HPV-18 confers resistance to TNF-alpha in organotypic cultures of human keratinocytes.

Boccardo E, Noya F, Broker TR, Chow LT, Villa LL.

Virology. 2004 Oct 25;328(2):233-43.

42.

Clonal selection for transcriptionally active viral oncogenes during progression to cancer.

Van Tine BA, Kappes JC, Banerjee NS, Knops J, Lai L, Steenbergen RD, Meijer CL, Snijders PJ, Chatis P, Broker TR, Moen PT Jr, Chow LT.

J Virol. 2004 Oct;78(20):11172-86.

43.

Global effects of human papillomavirus type 18 E6/E7 in an organotypic keratinocyte culture system.

Garner-Hamrick PA, Fostel JM, Chien WM, Banerjee NS, Chow LT, Broker TR, Fisher C.

J Virol. 2004 Sep;78(17):9041-50.

44.

Classification of papillomaviruses.

de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H.

Virology. 2004 Jun 20;324(1):17-27. Review.

45.

Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures.

Banerjee NS, Rivera AA, Wang M, Chow LT, Broker TR, Curiel DT, Nettelbeck DM.

Mol Cancer Ther. 2004 Apr;3(4):437-49.

46.

Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning.

Van Tine BA, Dao LD, Wu SY, Sonbuchner TM, Lin BY, Zou N, Chiang CM, Broker TR, Chow LT.

Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4030-5. Epub 2004 Mar 12.

47.

mRNA splicing regulates human papillomavirus type 11 E1 protein production and DNA replication.

Deng W, Jin G, Lin BY, Van Tine BA, Broker TR, Chow LT.

J Virol. 2003 Oct;77(19):10213-26.

48.

Activation of adenovirus early promoters and lytic phase in differentiated strata of organotypic cultures of human keratinocytes.

Noya F, Balagué C, Banerjee NS, Curiel DT, Broker TR, Chow LT.

J Virol. 2003 Jun;77(11):6533-40.

49.

Chaperone proteins abrogate inhibition of the human papillomavirus (HPV) E1 replicative helicase by the HPV E2 protein.

Lin BY, Makhov AM, Griffith JD, Broker TR, Chow LT.

Mol Cell Biol. 2002 Sep;22(18):6592-604.

50.

Transduction of the E6 and E7 genes of epidermodysplasia-verruciformis-associated human papillomaviruses alters human keratinocyte growth and differentiation in organotypic cultures.

Boxman IL, Mulder LH, Noya F, de Waard V, Gibbs S, Broker TR, ten Kate F, Chow LT, ter Schegget J.

J Invest Dermatol. 2001 Dec;117(6):1397-404.

Supplemental Content

Loading ...
Support Center